eyeforpharma Barcelona Conference, Expo & Awards 2019

eyeforpharma12 - 14 March 2019, Barcelona, Spain.
It's 2019, and it's time for something new. Attendance is ahead of expectations, eyeforpharma Barcelona is on track for over 1300 pharma decision makers from Sales, Marketing, Patient Engagement, Patient Advocacy, Medical Affairs, Digital, Market Access and RWE functions to fuse with health innovators, payers, patients, start-ups and cutting-edge tech.

On current projections, tickets will sell out this year. Ensure you have a place reserved at the only meeting where executives forge a new future for the pharma industry.

Medicine is just the beginning

Medicines are essential, yet they're rarely the entire solution. As we shift focus to outcomes, we need to be prepared to deliver value in whatever form is best for patients. The keynote sessions at eyeforpharma Barcelona will cover:
  • Value, driven.
    Change your mindset to reach beyond the incremental - and find bold solutions for real patients. Only then will outcomes be transformed.
  • Authenticity rules.
    Use greater patient insights to build trust with customers and fight for the best patient journey. Make education and credibility your mantra!
  • Tech is fundamental.
    See how digital ML & AI are delivering the data that rewrites your business plan, sets new standards and makes the connected future a reality.
  • Welcome new customers.
    Exceed elevated expectations by aligning to consumerisation - and setting new goals in wellbeing, prevention and regeneration.

New for 2019

The Innovation Stage

A showcase of bleeding-edge, industry-transforming science and new ideas which will open your eyes to the coming disruptions.

Real-World Evidence Europe Summit

For 2019 we've added our industry-leading Real-World Evidence Summit to the event to show the role RWE will play in the shift to value

The im-patient conference

Patient-focused conferences are usually designed by pharma. Until now! This time, patients have created the agenda and line-up.

Market Access Europe Summit

Market Access is vital for pharma's commercial success - that's why for 2019 it has been added as a key topic.

This is the world's biggest commercial pharma meeting and your opportunity to join 1300+ pharma leaders focused Sales, Marketing, Patient Engagement, Market Access, Medical Affairs and Real-World Evidence

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save €300 when you register here

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...